Weider focuses on eye health
This article was originally published in The Tan Sheet
Executive SummarySchiff Lutein will be "specially formulated with a higher level of zeaxanthin" than competing supplements because ingredient "is more concentrated in the middle of the fovea, where light impacts the retina," Salt Lake City-based Weider announces May 23. Eye health supplement contains 5 mg lutein, 1 mg zeaxanthin, as well as vitamins A, C, E, zinc and copper, and "helps promote healthy eyes by maintaining macular and retinal health," Weider says. Schiff Lutein will launch at food, drug and health stores nationwide in late spring; a 30-day supply will sell for $9.99-$15.99...
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.